J.A. Court

TL;DR: A genetic predisposition to lower D2 receptor expression may increase susceptibility to neuroleptic medication or clinical symptoms that are associated with diseases involving dopaminergic pathology.

TL;DR: Abnormalities of the nicotinic receptor in the diseases examined appear to be closely associated with primary histopathological changes: dopaminergic cell loss in Parkinson's disease and Lewy body dementia, amyloid plaques and tangles in subicular and entorhinal areas in Alzheimer's disease.

TL;DR: Investigation of dopaminergic activities along the rostrocaudal striatal axis from a post-mortem series indicated compensatory increased turnover in Parkinson's disease, which was absent in DLB despite the loss of substantia nigra neurons, dopamine and uptake sites.

TL;DR: Findings indicate a loss of the cerebellar nicotinic alpha4 receptor subunit in autism which may relate to the loss of Purkinje cells, and a compensatory increase in the alpha7 subunit.

TL;DR: Autopsy tissue from the temporal cortex of 14 AD cases and 15 age‐matched control subjects was compared using immunoblotting with antibodies against recombinant peptides specific for α3, α4, and α7 subunits, in conjunction with [3H]epibatidine binding to understand the role of nicotinic receptors in AD and potential therapeutic targets.